TD Asset Management Inc Sells 16,972 Shares of Zoetis Inc. $ZTS

TD Asset Management Inc lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,563,990 shares of the company’s stock after selling 16,972 shares during the period. TD Asset Management Inc’s holdings in Zoetis were worth $196,781,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZTS. Vanguard Group Inc. increased its holdings in shares of Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after acquiring an additional 5,474,210 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Zoetis by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after acquiring an additional 189,235 shares during the last quarter. Norges Bank acquired a new position in shares of Zoetis during the 4th quarter worth approximately $734,425,000. Nordea Investment Management AB increased its holdings in shares of Zoetis by 79.2% during the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after acquiring an additional 2,179,578 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Zoetis by 14.6% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock worth $631,046,000 after acquiring an additional 550,859 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling

In other news, Director Paul Bisaro bought 2,000 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Frank A. Damelio acquired 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 11,650 shares of company stock worth $886,384 in the last ninety days. 0.22% of the stock is owned by insiders.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $79.59 on Friday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The stock’s fifty day moving average price is $101.26 and its two-hundred day moving average price is $115.80. Zoetis Inc. has a one year low of $72.38 and a one year high of $171.52. The firm has a market cap of $33.37 billion, a price-to-earnings ratio of 13.20, a P/E/G ratio of 1.27 and a beta of 0.75.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same period in the prior year, the company earned $1.48 earnings per share. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.89 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is 35.16%.

Analyst Ratings Changes

ZTS has been the topic of a number of recent analyst reports. Bank of America boosted their target price on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. BTIG Research reissued a “buy” rating and set a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. Morgan Stanley reissued an “overweight” rating and set a $115.00 target price on shares of Zoetis in a report on Friday, May 15th. JPMorgan Chase & Co. decreased their target price on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Six research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has an average rating of “Hold” and an average target price of $133.92.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Investors are refocusing on Zoetis’ longer-term growth story, including its precision-animal-health expansion and planned Neogen animal genomics acquisition, which may be helping the stock rebound.
• Positive Sentiment: Unusual options activity showed increased call buying in ZTS, suggesting some traders are positioning for more upside.
• Neutral Sentiment: Zoetis released its 2025 Sustainability Report, highlighting progress in its “Driven to Care” strategy; this supports the company’s long-term narrative but is unlikely to move the stock much on its own. Article Title
• Negative Sentiment: Multiple law firms announced or expanded securities class action efforts against Zoetis, alleging investors were harmed by concealed FDA safety warnings and competitive market-share erosion; these headlines can weigh on the stock by raising legal and reputational risk. Article Title
• Negative Sentiment: Recent commentary also highlighted Zoetis’ underperformance versus healthcare peers and criticism from commentators, adding to the cautious tone around the name. Article Title

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.